NCT00575471View on ClinicalTrials.gov

Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Type 2 Diabetes
Interventions
DRUG

Rivoglitazone HCl

0.5 mg tablets once daily for 12 weeks

DRUG

rivoglitazone HCl

1.0 mg tablets once daily for 12 weeks

DRUG

rivoglitazone HCl

1.5 mg tablets once daily for 12 weeks

DRUG

Placebo

Matching placebo tablets once daily for 12 weeks

Trial Locations (3)

Unknown

Fukuoka

Osaka

Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY